Pediatrics, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
Pediatrics, University of Alberta Faculty of Medicine & Dentistry, Edmonton, Alberta, Canada.
Arch Dis Child Fetal Neonatal Ed. 2024 Feb 19;109(2):211-216. doi: 10.1136/archdischild-2023-325418.
To assess the neurodevelopmental outcomes of preterm neonates who received inhaled nitric oxide (iNO) in the first week of age for hypoxaemic respiratory failure (HRF).
In this retrospective cohort study, we included neonates born at <29 weeks gestational age (GA) between January 2010 and December 2018 who had a neurodevelopmental assessment at 18-24 months corrected age (CA) at one of the Canadian Neonatal Follow-Up Network clinics. The primary outcome was neurodevelopmental impairment (NDI). We performed propensity score-matched analysis to compare the outcomes of those who received and did not receive iNO.
Of the 5612 eligible neonates, 460 (8.2%) received iNO in the first week of age. Maternal age, receipt of antenatal corticosteroids, GA and birth weight were lower in the iNO group compared with the no-iNO group. Neonates in the iNO group had higher illness severity scores and higher rates of preterm prolonged rupture of membranes and were small for GA. Severe brain injury, bronchopulmonary dysplasia and mortality were higher in the iNO group. Of the 4889 survivors, 3754 (77%) neonates had follow-up data at 18-24 months CA. After propensity score matching, surviving infants who received rescue iNO were not associated with higher odds of NDI (adjusted OR 1.34; 95% CI 0.85 to 2.12).
In preterm neonates <29 weeks GA with HRF, rescue iNO use was not associated with worse neurodevelopmental outcomes among survivors who were assessed at 18-24 months CA.
评估在生命的第一周接受吸入一氧化氮(iNO)治疗的患有低氧性呼吸衰竭(HRF)的早产儿的神经发育结局。
在这项回顾性队列研究中,我们纳入了 2010 年 1 月至 2018 年 12 月期间出生且胎龄<29 周的新生儿,他们在加拿大新生儿随访网络的一家诊所接受了 18-24 个月校正年龄(CA)的神经发育评估。主要结局是神经发育障碍(NDI)。我们进行了倾向评分匹配分析,以比较接受和未接受 iNO 治疗的患儿的结局。
在 5612 名符合条件的新生儿中,有 460 名(8.2%)在生命的第一周接受了 iNO 治疗。与未接受 iNO 治疗的患儿相比,iNO 组的产妇年龄、接受产前皮质激素治疗、胎龄和出生体重较低。iNO 组的患儿疾病严重程度评分较高,且早产儿胎膜早破时间延长和胎龄小的比例较高。iNO 组的严重脑损伤、支气管肺发育不良和死亡率较高。在 4889 名幸存者中,有 3754 名(77%)新生儿在 18-24 个月 CA 时具有随访数据。经过倾向评分匹配后,接受挽救性 iNO 治疗的存活婴儿的 NDI 发生风险无显著增加(调整后的 OR 1.34;95%CI 0.85 至 2.12)。
在胎龄<29 周且患有 HRF 的早产儿中,在接受 18-24 个月 CA 评估时,挽救性 iNO 的使用与幸存者的神经发育结局无显著相关性。